Eton Pharmaceuticals, Inc. (ETON)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$58.45-2.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ETON
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Raise full year 2026 revenue guidance to exceed $145 million, driven by product sales growth and new product launches.
Stated as a priority in 2 of last 2 quarters. Management raised 2026 revenue guidance from over $120 million in 2026-Q1 to now exceed $145 million in 2026-Q2. Q2 2026 product sales were $37.6 million, a 99% increase year-over-year, reflecting strong portfolio growth and new product launches. The trajectory is delivering against the raised revenue guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Raising full year revenue guidance, with 2026 revenue now expected to exceed $145 million, up from previous guidance of more than $120 million.”
“Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million.”
Maintain adjusted gross margin above 70% for full year 2026 despite product mix changes and milestone expenses.
Stated in 2 of last 2 quarters. Adjusted gross margin was 67% in 2026-Q1 and improved to 73% in 2026-Q2, despite higher sales of margin-dilutive products. Management expects full year adjusted gross margin to exceed 70%, including milestone expenses. The trajectory shows progress toward the margin target.
“The Company expects full year 2026 adjusted gross margin to exceed 70%, inclusive of the potential $4 million commercial milestone.”
“The Company expects full year 2026 adjusted gross margin to exceed 70%.”
Increase Adjusted EBITDA margin guidance from 30% to at least 35% for full year 2026, reflecting operational leverage and growth.
Stated in 2 of last 2 quarters. Adjusted EBITDA margin improved from 24% in 2026-Q1 to 43% in 2026-Q2, exceeding prior guidance. Management raised full year 2026 Adjusted EBITDA margin guidance from at least 30% to at least 35%, reflecting operational leverage and growth. The trajectory is delivering.
“We now expect to deliver an Adjusted EBITDA margin of at least 35%.”
“The Company expects to report at least a 30% Adjusted EBITDA margin for full year 2026.”
Grow rare disease portfolio by acquiring and licensing late-stage product candidates and commercialization rights.
Stated in 2 of last 2 quarters. Management completed acquisitions and licensing agreements for late-stage candidates ASN-001 and IMPAVIDO, expanding the product portfolio. These strategic moves complement existing products and support growth. The trajectory shows active portfolio expansion.
“Acquired late-stage product candidate ASN-001, expanding the Company’s infantile hemangioma franchise.”
“Acquired and relaunched HEMANGEOL; announced initiation of ET-700 clinical study.”
Submit FDA Prior Approval Supplement to broaden KHINDIVI indication to children under five years old.
Newly stated in 2026-Q3. Management submitted a Prior Approval Supplement to FDA to expand KHINDIVI's label to include younger pediatric patients under age five, aiming for potential approval in first half 2027. This is a recent regulatory initiative with no prior quarters stating this priority.
“Submitted Prior Approval Supplement to the FDA requesting expansion of KHINDIVI indication to younger pediatric patients.”
Over the trailing year it converted -2.41x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
18 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.